Alpha-methylacyl-CoA racemase: A multi-institutional study of a new prostate cancer marker

Histopathology

Volumn 45, Issue 3, 2004, Pages 218-225

  Jiang, Z ^a   Wu, C L ^b   Woda, B A ^a   Iczkowski, K A ^c   Chu, P G ^d   Tretiakova, M S ^e   Young, R H ^b   Weiss, L M ^d   Blute Jr , R D ^a   Brendler, C B ^e   Krausz, T ^e   Xu, J C ^f   Rock, K L ^a   Amin, M B ^g   Yang, Ximing J ^e,h,i  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

^d CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^e UNIVERSITY OF CHICAGO   (United States)

^f GLAXOSMITHKLINE   (United States)

^g EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h NORTHWESTERN UNIVERSITY   (United States)

ⁱ NORTHWESTERN MEMORIAL HOSPITAL   (United States)

Author keywords

methylacyl CoA racemase; AMACR; Biomarker; P504S; Prostate cancer

Indexed keywords

2 METHYLACYL COENZYME A RACEMASE; MESSENGER RNA; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; AUTOMATION; BENIGN TUMOR; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE MARKER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NEEDLE BIOPSY; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATE TUMOR; PROSTATECTOMY; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; TRANSURETHRAL RESECTION; VALIDATION PROCESS;

ADENOCARCINOMA; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; PROSTATIC NEOPLASMS; RACEMASES AND EPIMERASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 4644372687     PISSN: 03090167     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2004.01930.x     Document Type: Article

References (27)

1. Wang MC, Papsidero LD, Kuriyama M, Valenzuela LA, Murphy GP, Chu TM. Prostate antigen: a new potential marker for prostatic cancer. Prostate 1981; 2; 89-96.
2. Catalona WJ, Richie JP, Ahmann FR et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J. Urol 1994; 151; 1283-1290.
3. Epstein JI. PSAP and PSA as immunohistochemical markers. Urologic Clin. N. Am. 1993; 20; 757-770.
4. Polascik TJ, Oesterling JE, Partin AW. Prostate specific antigen: a decade of discovery-what have we learned and where are we going. J. Urol. 1999; 162; 293-306.
5. Hasui Y, Marutsuka K, Asada Y et al. Relationship between serum prostate specific antigen and histological prostatitis in patients with benign prostatic hyperplasia. Prostate 1994; 25; 91-96.
6. Nadler RB, Humphrey PA, Smith DS et al. Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J. Urol 1995; 154; 407-413.
7. Epstein JI. Diagnostic criteria of limited adenocarcinoma of the prostate on needle biopsy. Hum. Pathol. 1995; 26; 233-239.
8. Young RH, Sringley JR, Amin MB et al. Tumors of the prostate glands, seminal vesicles, male urethra, and penis. Third series. Washington. DC: Armed Forces Institute of Pathology, 2000; 154-175; 289-344.
9. Epstein JI, Yang XJ. Prostate biopsy interpretation, 3rd edn. Philadelphia: Lippincott Williams & Wilkins, 2002; 64-91.
10. Xu J, Stolk JA, Zhang X et al. Identification of differentially expressed genes in human prostate cancer using subtraction and microarray. Cancer Res. 2000; 60; 1677-1682.
11. Jiang Z, Woda BA, Rock KL et al. P504S: a new molecular marker for the detection of prostate carcinoma. Am. J. Surg. Pathol. 2001; 25; 1397-1404.
12. Rubin MA, Zhou M, Dhanasekaran SM et al. α-methylacyl coenzyme a racemase as a tissue biomarker for prostate cancer. JAMA 2002; 287; 1662-1670.
13. Lou J, Zha S, Gage WR et al. α-methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res. 2002; 62; 2220-2226.
14. Gown AM, Vogel AM. Monoclonal antibodies to human intermediate filament proteins: distribution of filament proteins in normal human tissues. Am. J. Pathol 1984; 114; 309-321.
15. Wojno KJ, Epstein JI. The utility of basal cell-specific anticytokeratin antibody (34βE12) in the diagnosis of prostate cancer. Am. J. Surg. Pathol. 1995; 19; 251-260.
16. Jiang Y, Harlocker S, Molesh DA et al. Discovery of breast cancer antigens using subtraction cDNA libraries and cDNA microarray. Oncogene 2002; 21; 2270-2282.
17. Schena M, Shalon D, Davis RW et al. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 1995; 20; 467-470.
18. Lockhart DJ, Winzeler EA. Genomics, gene expression and DNA arrays. Nature 2001; 405; 827-836.
19. Welsh JB, Sapinoso LM, Su AI et al. Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res. 2001; 61; 5974-5993.
20. Griffith RC, Epstein JI. Review of prostate needle biopsies by an expert. Mod. Pathol. 2001; 14; 110A.
21. Magee JA, Araki T, Patil S et al Expression profiling reveals hepsin overexpression in prostate cancer. Cancer Res. 2001; 61; 5692-5696.
22. Stamey TA, Warrington JA, Caldwell MC et al. Molecular genetic profiling of Gleason grade 4/5 prostate cancers compared to benign prostatic hyperplasia. J. Urol. 2001; 166; 2171-2177.
23. Dhanasekaran SM, Barrette TR, Ghosh D et al. Delineation of prognostic biomarkers in prostate cancer. Nature 2001; 412; 822-826.
24. Yang XJ, Wu CL, Woda BA et al. Expression of α-methylacyl Co A racemase (P504S) in atypical adenomatous hyperplasia of the prostate. Am. J. Surg. Pathol 2002; 26; 921-925.
25. Giovannucci E, Rimm EB, Colditz GA et al. A prospective study of dietary fat and risk of prostate cancer. J. Natl Cancer Inst. 1993; 85; 1571-1579.
26. Le Marchand L, Kolonel LN, Wilkens LR et al. Animal fat consumption and prostate cancer: a prospective study in Hawaii. Epidemiology 1994; 5; 276-282.
27. Ferdinandusse S, Denis SIJ, Ist L et al. Subcellular localization and physiological role of a α-methylacyl-CoA racemase. J. Lipid Res. 2000; 41; 1890-1896.